Key result
Cell therapy for ischemic stroke shows pre-clinical promise, but warrants rigorous clinical trials.
While acute neuroprotection in acute stroke has proven difficult and ended in many failures, there is increasing interest in restorative therapies that target brain remodelling. Cell therapy (transplantation of cells) shows promise, with a growing body of pre-clinical evidence demonstrating improved functional outcomes in animal models; however, questions still remain concerning mechanisms of action. Clinical trials are already underway and will increase in the next few years; their appropriate design and execution along with continued pre-clinical work are necessary for the field to advance and satisfy a large unmet clinical need.
No takes yet. Share an insight, caveat, or question.
Hess et al. (2011) conducted a review in Ischaemic stroke. Cell therapy was evaluated. Cell therapy for ischaemic stroke shows promise in pre-clinical models, but rigorous clinical trials and continued pre-clinical work are needed to advance the field and address unmet clinical needs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: